<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02669680</url>
  </required_header>
  <id_info>
    <org_study_id>GRAFT</org_study_id>
    <nct_id>NCT02669680</nct_id>
  </id_info>
  <brief_title>Granulocyte Colony Stimulating Factor (G-CSF) to Treat Acute-on-chronic Liver Failure</brief_title>
  <official_title>Granulocyte Colony Stimulating Factor (G-CSF) to Treat Acute-on-chronic Liver Failure: A Multicentre Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leipzig</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Leipzig</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicentre, open, randomised, and controlled trial conducted in patients diagnosed with
      acute on chronic liver failure (ACLF) who meet inclusion/exclusion criteria.The objective of
      GRAFT-trial is to evaluate efficacy and safety of subcutaneously administered granulocyte
      colony-stimulating factor (G-CSF) in patients with ACLF. All patients will receive standard
      medical care for ACLF according to the guidelines. Patients in the experimental arm
      additional receive subcutaneous injections of G-CSF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The acute on chronic liver failure (ACLF) is characterised by a severe deterioration of liver
      function due to a precipitating event on top of an underlying chronic liver disease. As
      therapeutic options are limited the mortality rate lies between 40 and 80% at 3 months. The
      granulocyte colony-stimulating factor (G-CSF) mobilized stem- as well as immune cells and
      improved liver function in preclinical trials. G-CSF treatment reduced the rate of infectious
      complications and significantly improved patients´ survival in acute on chronic liver
      failure, shown recently in small randomised studies. Thus, G-CSF is a promising treatment
      option that needs to be evaluated in a multi-centre controlled trial. The GRAFT trial will
      randomise patients with ACLF between standard of care with and without G-CSF. All
      participants will be followed for 12 months in order to evaluate safety and efficacy of
      G-CSF. If successful, the GRAFT trial has the potential to change clinical practice in acute
      on chronic liver failure.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Transplant-free survival up to 90 days (death or transplant count as events)</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival time until the end of follow-up</measure>
    <time_frame>360 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant-free survival time until the end of follow-up</measure>
    <time_frame>360 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications of ACLF (hepatorenal syndrome (HRS), variceal bleeding, ascites, hepatic encephalopathy (HE))</measure>
    <time_frame>90 days/360 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infections (proven infection necessitating systemic use of antibiotics)</measure>
    <time_frame>90 days/360 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver function - assessed by MELD-Score - during the course of treatment and follow-up</measure>
    <time_frame>360 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver function - assessed by Child-Pugh-Score - during the course of treatment and follow-up</measure>
    <time_frame>360 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of the initial hospital stay</measure>
    <time_frame>up to 360 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">176</enrollment>
  <condition>Acute-On-Chronic Liver Failure</condition>
  <arm_group>
    <arm_group_label>G-CSF + Standard therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard care of acute-on-chronic liver failure and application of G-CSF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard care of acute-on-chronic liver failure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>G-CSF subcutaneously, 5 μg/kg daily on day 0-4, then every 3rd day over 26 days (days 7, 10, 13, 16, 19, 22, 25) = 12 doses</description>
    <arm_group_label>G-CSF + Standard therapy</arm_group_label>
    <other_name>Filgrastim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard therapy</intervention_name>
    <arm_group_label>G-CSF + Standard therapy</arm_group_label>
    <arm_group_label>Standard therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Acute-on-chronic liver failure (ACLF) according to the consensus criteria recently
             defined by the CANONIC study group [Moreau 2013]. Patients with acute decompensation
             of cirrhosis [defined as acute development of one or more of the following: ascites
             (onset and/or worsening), hepatic encephalopathy (onset and/or worsening),
             gastrointestinal haemorrhage, bacterial infection] are classified as ACLF if one of
             the following applies:

               -  single kidney failure (serum creatinine level ≥ 2 mg/dl) or

               -  single failure of one of the following organ systems: liver, coagulation,
                  circulation, or respiration, together with a serum creatinine level ranging from
                  1.5 to &lt; 2.0 mg/dl and/or mild to moderate hepatic encephalopathy or

               -  single cerebral failure together with serum creatinine level ranging from 1.5 to
                  &lt; 2.0 mg/dl or

               -  two or more organ failures. Organ failures are defined according to the CLIF-C
                  OFs [Jalan 2014].

          2. Age ≥ 18 years, male or female

          3. Written informed consent from patient, legal or authorized representative or a
             confirmation of justification of trial participation by an independent medical
             consultant PLEASE NOTE: In case of confirmation by the independent medical consultant
             a deferred informed consent from patient, legal or authorized representative has to be
             given

        Exclusion Criteria:

          1. Prior not curatively treated or active malignancies

          2. Sickle cell disease

          3. septic shock, defined by the following symptom complex: bacteraemia AND SIRS AND shock

          4. WBC-count of &gt; 50 x 109/L

          5. Known HIV infection

          6. Known intolerance to filgrastim

          7. Suspected lack of compliance

          8. Pregnant or nursing women

          9. Fertile women (within two years of their last menstruation) without appropriate
             contraceptive measures (implanon, injections, oral contraceptives, intrauterine
             devices, partner with vasectomy) while participating in the trial (participants using
             a hormone-based method have to be informed of possible effects from the trial
             medication on contraception).

         10. Participation in other interventional trials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Berg, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital of Leipzig;</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Leipzig</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Aachen</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité-Campus Virchow-Klinikum</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der J.W. Goethe- Universität</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle (Saale)</name>
      <address>
        <city>Halle</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum KÖLN</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HELIOS Park-Klinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum St. Georg gGmbH</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Magdeburg AöR</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Josefs-Hospital</name>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>January 22, 2016</study_first_submitted>
  <study_first_submitted_qc>January 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2016</study_first_posted>
  <last_update_submitted>September 27, 2019</last_update_submitted>
  <last_update_submitted_qc>September 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Leipzig</investigator_affiliation>
    <investigator_full_name>Thomas Berg</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
    <mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

